Latest Clinical Trials News

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.

Hydrix has landed a A$3.4 million contract with US-based Remedy Robotics to develop safety-critical software and embedded electronics for the N1 robotic system, marking a major step in its medical robotics ambitions.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

Starpharma Holdings is raising approximately $32 million through a fully underwritten 1-for-7.5 renounceable entitlement offer priced at $0.57 per share, discounting the stock by 25%. Proceeds will fund the DEP HER2-Lu Phase 1 trial and expand its dendrimer-based oncology pipeline.

Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

TrivarX has locked in investigational product supply critical for starting its Phase 1 clinical trial of the Stabl-Im MRI imaging platform, targeting a 2026 trial commencement.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.